HCWB · HCW Biologics Inc.

HCW Biologics reported financial results for Q4 and FY 2025, showing a stark revenue decline to $27K in Q4 from $395K year-ago quarter and $54K for the full year from $2.6M prior year, primarily due to a one-year suspension of the Wugen license agreement in exchange for rights to market HCW9206 and HCW9201 as reagents. R&D expenses rose 27% to $1.3M in Q4 on manufacturing but fell 15% annually to $5.4M. G&A decreased 26% quarterly to $1.5M but increased 13% yearly to $7.7M from salaries, audit, and compliance costs. A key driver of the Q4 net gain of $2.2M (vs $3.4M loss prior) and reduced FY loss of $6.5M (vs $30M) was a $1.5M net legal recovery from a $2.0M insurance reimbursement and $5.5M settlement gain related to arbitration defense for CEO Dr. Hing C. Wong. Business highlights include Phase 1 initiation of lead candidate HCW9302 for alopecia areata, affecting 7M US patients with no curative FDA treatments, with data due H1 2026. CEO Wong highlighted preclinical advantages in Treg expansion, tolerability, and dose efficiency over conventional IL-2. Licensing progress featured $2.9M net upfront for HCW11-006 to Trimmune, plus equity, milestones, royalties, and opt-in rights. Commercial reagent launches of HCW9206 and HCW9201 aim to generate revenue, bolstered by a Science Advances publication on CAR-T manufacturing improvements. However, substantial going concern doubt persists without additional funding, despite Nasdaq compliance reinstatement on Feb 26, 2026, now under monitor, and a fresh Mar 26 bid price violation notice post-reverse split, prompting an appeal.